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The cardinal virulence factor of human-pathogenic enterohaemorrhagic Escherichia coli (EHEC) is Shiga 
toxin (Stx), which causes severe extraintestinal complications including kidney failure by damaging 
renal endothelial cells. In EHEC pathogenesis, the disturbance of the kidney epithelium by Stx becomes 
increasingly recognised, but how this exactly occurs is unknown. To explore this molecularly, we 
investigated the Stx receptor content and transcriptomic profile of two human renal epithelial cell lines: 
highly Stx-sensitive ACHN cells and largely Stx-insensitive Caki-2 cells. Though both lines exhibited the 
Stx receptor globotriaosylceramide, RNAseq revealed strikingly different transcriptomic responses 
to an Stx challenge. Using RNAi to silence factors involved in ACHN cells’ Stx response, the greatest 
protection occurred when silencing RAB5A and TRAPPC6B, two host factors that we newly link to Stx 
trafficking. Silencing these factors alongside YKT6 fully prevented the cytotoxic Stx effect. Overall, our 
approach reveals novel subcellular targets for potential therapies against Stx-mediated kidney failure.
Gastrointestinal infections by enterohaemorrhagic Escherichia coli (EHEC), a highly pathogenic human subgroup 
of Shiga toxin (Stx)-producing Escherichia coli, cause haemorrhagic colitis and life-threatening extraintestinal 
complications such as haemolytic-uraemic syndrome (HUS)1. HUS is characterised by the triad of thrombocyto-
penia, microangiopathic haemolytic anaemia, and acute renal failure and can also lead to neurological sequelae2,3. 
Infections caused by EHEC are still a major global health threat, especially to children4, and antibiotic treatment 
is highly controversial5,6. Thus, no conclusive treatment is available beyond supportive care.
Mounting evidence has indicated that EHEC affects more cell types than originally thought. In the first step, 
EHEC attaches to the intestinal epithelium. There the cardinal virulence factor Stx — which occurs in two major 
types, Stx1 and Stx2, each of which have their own subtypes; subtype Stx2a is most often correlated with severe 
disease outcome7 — is translocated into the bloodstream by an incompletely understood mechanism8. After dis-
semination through the bloodstream, Stx enters the kidney and primarily targets microvascular endothelial cells 
of the glomeruli9,10, but it may also target renal epithelial cells11,12. The possible engagement of the renal epithe-
lium in Stx intoxication was first indicated upon detecting the main Stx receptor, the glycosphingolipid (GSL) 
globotriaosylceramide (Gb3Cer; also known as CD77 [Galα1-4Galβ1-4Glcβ1-1Cer]), in the human kidney cor-
tex and medulla13. Later, more evidence was found, specifically renal tubular injuries by Stx14 and Stx-induced 
apoptosis in kidney cortices of HUS patients and human renal tubular epithelial cells15. Subsequently, various 
renal epithelial cell types were found to be Stx-sensitive16–19. However, precisely how renal epithelial cells are 
affected by Stx is mostly unspecified.
Stx belongs to the family of AB5 toxins in which the A subunit is catalytically active and the B subunit binds 
to host targets20–23. Specifically, the Stx B subunit binds to Gb3Cer, the dominant receptor on human endothelial 
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cells12, after which Stx is internalised by clathrin-dependent and -independent endocytic processes22,24 and then 
intracellularly trafficked in a variety of cells. In this process, Stx is transported in a retrograde manner, first from 
the early endosome (EE) to the trans-Golgi Network (TGN) and then via the Golgi apparatus to the endoplasmic 
reticulum (ER)20–22,25,26. During retrograde passage, the Stx A subunit is cleaved into the A1 and A2 fragments, 
after which the A1 fragment is retrotranslocated from the ER to the cytosol. Here, it exerts its ribosomal RNA 
N-glycosidase activity catalysing the depurination of a specific adenosine of the 28 S ribosomal RNA, which leads 
to the inhibition of protein biosynthesis and ultimately cell death27,28. Yet, while the uptake and trafficking process 
of Stx has been intensively studied, many features are still obscure and are under investigation21,22,24.
Interestingly, certain renal epithelial cell lines have been found to have different reactions to Stx: ACHN cells 
seem to have high sensitivity towards Stx29, but, in remarkable contrast, Caki-2 cells are nearly unresponsive to 
Stx30. As both cell lines similarly exhibit characteristics of renal distant tubular epithelial cells31, the reason for 
their opposing Stx sensitivities is confounding. One possibility is that these differences may be related to Stx 
receptor content and/or how Stx is taken up or trafficked in these cell lines.
To solve this apparent conundrum in Stx sensitivity and, thus, to generally elucidate the effect of Stx on 
renal epithelial cells, here we first reevaluated this contrasting phenotype. Next, we showed that the Stx receptor 
Gb3Cer is accessible and present in both ACHN and Caki-2 cells, indicating that differences in Stx sensitivity 
are not due to differences related to the Stx receptor. Then, to unravel the underlying cellular variation, we per-
formed RNA sequencing (RNAseq). We found that upon Stx challenge, many genes exhibited profound differen-
tial expression, including trafficking-related genes. By applying RNA interference (RNAi), we were able to identify 
that knockdowns of RAB5A, TRAPPC6B, and YKT6 made highly sensitive ACHN cells practically refractory to 
Stx2a. Overall, this study shows that the distinct Stx sensitivity phenotypes of two similar renal epithelial cell lines 
serve as an excellent model for gaining insights into cellular susceptibility to Stx, and it proposes new targets for 
inactivating the cytotoxic action of Stx2a, potentially offering an avenue for future treatment of EHEC infections.
Results
ACHN cells are highly sensitive to Stx2a, while Caki-2 cells are largely refractory. ACHN and 
Caki-2 cells were incubated with affinity-purified, endotoxin-free Stx2a (Fig. S1), the Stx subtype with the highest 
clinical relevance, in contrast to previous studies performed with Stx129,30. Increasing Stx2a concentrations of 
0.5 pg/mL, 0.5 ng/mL, and 0.5 μg/mL were used, and cell viability was determined after 72 h of toxin exposure, as 
shown in Fig. 1. Strikingly, ACHN cells were highly sensitive to Stx2a, showing a remarkable decrease in viabil-
ity at 0.5 ng/mL Stx2a, where only 13.4% of cells survived (always compared to control cells); this was a drastic 
reduction from the cell viability of 86.8% at the particularly low Stx2a concentration of 0.5 pg/mL. At the highest 
Stx2a concentration of 0.5 μg/mL, only 1.0% of ACHN cells survived, indicating the cell culture had entirely col-
lapsed. In contrast, Caki-2 cells were largely refractory to Stx2a exposure at 0.5 pg/mL and 0.5 ng/mL, showing 
only a negligible decrease in viability. Only at the highest concentration of 0.5 μg/mL was there a moderate but 
significant decrease to 87.1% survival. As ACHN cells only showed a comparable level of survival when exposed 
to the lowest concentration of 0.5 pg/mL Stx2a (86.8%), these results show that Caki-2 cells were 106 times less 
susceptible to the toxin. Thus, ACHN and Caki-2 cells exhibit diametrically opposite Stx susceptibility.
ACHN and Caki-2 epithelial cells exhibit virtually identical Gb3Cer profiles. To elucidate the 
observed sharp difference in toxin sensitivity of the two epithelial cell lines, we first examined the cellular binding 
Figure 1. Differing susceptibility of ACHN and Caki-2 cells towards Stx2a. ACHN and Caki-2 cells were 
incubated for 72 h with increasing Stx2a concentrations as indicated. Cell viability represents percentage 
values compared to respective controls and is presented as boxplots: The central rectangle corresponds to the 
interquartile range, the horizontal line shows the median, and the “whiskers” are 1.5x of the interquartile range. 
Triplicate measurements of three biological replicates (n = 3) are shown in distinct colours (orange, magenta, 
and blue). Asterisks above boxplots denote the levels of significance in relation to the corresponding control: 
**p < 0.01; ***p < 0.001.
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of Stx2a and the presence of the main human Stx receptor, GSL Gb3Cer, which is required for binding and sub-
sequent internalisation of the toxin9.
Applying fluorescence microscopy, we morphologically evaluated cell surface-bound Stx2a, using wheat germ 
agglutinin (WGA) as a common lectin for normalised prestaining of readily available carbohydrates as a surrogate 
for the total cell surface (Fig. S2). For ACHN cells, this showed either a rather weak but markedly punctate Stx2a 
staining (Fig. S2a,c), or a distinct toxin signal enrichment on the overall cell surface (Fig. S2a,d). For Caki-2 cells, 
a very uniform Stx2a staining was observed (Fig. S2b,e). Quantitative analysis of the toxin binding (for details 
see Methods) revealed that both cell lines exhibited a significant increase of the Stx2a/WGA fluorescence inten-
sity ratio compared to the corresponding mock-stained samples: for Caki-2 cells the Stx2a-associated increase 
amounted to 0.13 above the background, whereas ACHN cells displayed a more robust increase of 0.58.
However, although one might think this could explain the cell lines’ differences in Stx sensitivity, the observed 
differences in toxin binding and/or cell accessibility actually cannot fully explain the strikingly distinct sensitivi-
ties, as even one single Stx molecule is sufficient to induce cell death in bound cells32.
To elucidate whether the differences in toxin binding are reflected in the global Stx receptor profiles, we next 
performed an in-depth investigation of the GSL composition of ACHN and Caki-2 cells. Initially, GSLs were 
extracted from ACHN and Caki-2 cells, and the overall GSL patterns were obtained by thin-layer chromatog-
raphy (TLC) separation (Fig. 2a). The orcinol-stained GSLs suggested the presence of monohexosylceramide 
(MHC), lactosylceramide (Lc2Cer), Gb3Cer, and globotetraosylceramide (Gb4Cer), each with varying lipoforms 
separating as double bands on the chromatogram. Surprisingly, both cell lines showed comparable GSL patterns 
Figure 2. GSL profiles of ACHN and Caki-2 cells and mass spectra of Gb3Cer. (a) Orcinol stains of 
TLC-separated GSLs isolated from ACHN and Caki-2 cells. MHC – monohexosylceramide, Lc2Cer – 
lactosylceramide, Gb3Cer – globotriaosylceramide, Gb4Cer – globotetraosylceramide. GSLs applied in (a,b) 
correspond to 4 × 106 cells and were separated alongside 10 µg (a) or 4 µg (b) of reference GSLs from human 
erythrocytes (R). (b) TLC overlay chromatogram and the scheme of the basic principle of Stx2a-mediated 
detection of GSL receptors. Bound anti-Stx2 antibodies were detected with alkaline phosphatase (AP)-
conjugated secondary antibody (Ab) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) as substrate. (c) ESI 
mass spectra showing the various lipoforms of Gb3Cer of ACHN and Caki-2 cells.
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with minor differences in presumed Lc2Cer and Gb4Cer content as well as unknown GSLs separating below 
Gb4Cer (Fig. 2a). Because Stx2a preferentially binds to Gb3Cer9, we subsequently focused on Gb3Cer in solid 
phase binding assays and mass spectrometric characterisation.
Identical Gb3Cer double bands were immunochemically detected with Stx2a in TLC overlay assays for both 
cell lines (Fig. 2b). Afterwards, the exact structures of the various Gb3Cer lipoforms of ACHN and Caki-2 cells 
were identified using electrospray ionisation (ESI) mass spectrometry (MS) as shown with the MS1 spectra pre-
sented in Fig. 2c. Both ACHN and Caki-2 cell lines exhibit variable content of Gb3Cer species due to ceramide 
moieties harbouring d18:1 sphingosine linked to a C16:0, C22:0, C22:1, or C24:1 fatty acid. Verification of the 
proposed structures was done by collision-induced (CID) MS, and representative MS2 spectra of identified 
Gb3Cer species with fragmentation schemes are shown for ACHN and Caki-2 cells in Fig. S3a,b, respectively. 
However, we measured here total GSLs in the cellular extracts and it was not possible to distinguish between GSLs 
exposed on the cell surface and GSLs localized intracellularly.
Collectively, even though ACHN and Caki-2 cells show topographically different cellular Stx attachment, they 
display comparable Gb3Cer lipoforms, as shown by TLC Stx2a overlay immunoassays and verified by MS analy-
sis. This indicates that additional factors are likely contributing towards the cell lines’ contrasting Stx sensitivity.
RNAseq reveals profound gene expression differences between ACHN and Caki-2 cells in response 
to Stx2a. To gain cell physiological insights into the opposing susceptibility of the Stx-sensitive ACHN versus 
the de facto Stx-refractory Caki-2 cells, we performed RNAseq. The cells were exposed to Stx2a for 4 h or 8 h, and 
the results were compared to a control at starting conditions without Stx2a. An overall sequencing summary of 
the RNAseq run is presented in Table S1. Next, we performed exploratory data analysis and assessed the overall 
similarity between the two cell lines and between 4 h or 8 h Stx2a exposure and the control by applying principal 
component analysis (PCA). PCA revealed, first, a clear distinction between ACHN and Caki-2 cells globally. 
Second, it also revealed a distinction between Stx2a exposure and control conditions, though the difference was 
more pronounced with ACHN cells than with Caki-2 cells (Fig. 3a).
Then, we examined the transcriptomic response to Stx2a exposure in more detail, disregarding those genes 
with a less than twofold difference versus control conditions. Toxin-sensitive ACHN cells exhibited a gener-
ally strong response, with 1,141 significantly differentially expressed genes upon 4 h Stx2a exposure; many of 
these genes were highly upregulated, and the ratio of up- to downregulated genes was 4.1 (Fig. 3b, left panel). 
Prolonging Stx2a exposure to 8 h more than doubled this number, resulting in 2,772 significantly differentially 
expressed genes, and the up-to-down ratio was reduced to 1.8 (Fig. 3b, right panel). In contrast, toxin-refractory 
Caki-2 cells showed only a mild response, with 69 genes at 4 h Stx2a exposure of which many were highly down-
regulated; still, the up-to-down ratio was 4.0 (Fig. 3c, left panel). Exposing Caki-2 cells to Stx2a for 8 h altered this 
number only marginally to 64 genes, and the up-to-down ratio increased to 5.5 (Fig. 3c, right panel).
Interestingly, looking more closely at the top 20 genes with the highest variability in ACHN and Caki-2 cells 
across conditions (Fig. 4) shows that 8 out of these 20 genes upregulated by Stx2a exposure are shared by both cell 
lines, namely: FOSB, ATF3, DUSP1, EGR1, EGR2, IL6, TRAF1, and TNFAIP3. This highlights that both cell lines 
react to Stx2a exposure. Altogether, despite some overlap, a much stronger transcriptomic response to Stx2a of 
toxin-sensitive ACHN cells was detected when compared to toxin-resistant Caki-2 cells.
Interaction analysis discloses clusters of differentially expressed genes of ACHN versus Caki-2 
cells in retrograde trafficking. As our main objective was to decipher the cellular attributes responsible for 
these cell lines’ diverging sensitivity to Stx, we performed time series analysis that included in the statistical model 
both ACHN and Caki-2 cells as well as the three experimental conditions, i.e. Stx2a exposure for 4 h, for 8 h, or no 
Stx2a exposure (control). The output of this analysis was a list of genes which behaved in a cell-specific manner 
over time. Genes in both ACHN and Caki-2 cells that similarly moved up or down in response to Stx2a were not 
given small p-values by the model and, thus, were excluded from further analysis (for details see Methods). By 
analysing the top 2,000 differentially expressed genes of ACHN versus Caki-2 cells, it became apparent that many 
play a role in endocytosis and intracellular retrograde trafficking of Stx21,22. In general, the involved host proteins 
comprise numerous vesicle lifecycle factors, i.a. RAB GTPases such as RAB6A as the master regulator, or cytoskel-
eton components like the microtubules and its minus-end-directed motor protein complex dynein for transport. 
Furthermore, Stx trafficking also involves vesicle tethering factors such as golgins or the conserved oligomeric 
Golgi (COG) or Golgi-associated retrograde protein (GARP) complexes and different SNAREs, which are mem-
brane fusion mediators. Genes from the top 2,000 list representing such host factors are summarised in Table 1 
(for the corresponding references see Table S2). Consequently, our approach demonstrates a valid way to explore 
potential cellular differences in Stx sensitivity, and it prompted us to investigate trafficking-related genes in detail.
For this purpose, we first extracted all genes exhibiting a higher expression in ACHN versus Caki-2 cells from 
the top 2,000 collection that localize in/at the endosomal system, the Golgi network or the ER, including the 
TGN, the cis-Golgi network, and the ER-Golgi intermediate compartment according to Gene Ontology terms 
(Table S3). Hereafter, we visualised the interaction of these 143 genes using the STRING database (Fig. 5). This 
interaction network shows several clusters, with one cluster (i) predominantly containing factors involved in 
intracellular retrograde trafficking, supporting our previous assumption. Another cluster (ii) largely contains 
factors of the ESCRT (endosomal sorting complexes required for transport) pathway, which also contributes 
to intracellular trafficking. Importantly, the central node that connects both of the clusters is the gene RAB5A. 
Hence, by performing interaction analysis of selected differentially expressed genes in ACHN versus Caki-2 cells, 
we determined distinct clusters containing genes participating in the retrograde trafficking pathway.
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RNAseq highlights that certain trafficking genes in ACHN cells could be silenced to inhibit Stx 
cytotoxic action. As the ACHN RNAseq data showed a clustering of factors related to intracellular retro-
grade trafficking (Fig. 5), this indicates that the retro-routing of Stx to its subcellular targets plays a crucial role in 
ACHN cells’ high sensitivity to Stx2a compared to that of Caki-2 cells. To further explore the RNAseq data and to 
test the physiological relevance of the host factors identified, we applied RNAi with small interfering RNAs (siR-
NAs) to ACHN cells. The rationale is that by knocking down specific cellular targets, we should be able to make 
ACHN cells insensitive to the cytotoxic action of Stx2a (‘refractory effect’).
To this end, we selected a set of targets along Stx’s retrograde trafficking route, i.e. mainly components of 
the endosomal system, the Golgi apparatus and the ER. The subcellular localisation of the targets is portrayed 
in Fig. 6, and additional explanations regarding their biological role are provided in Table 1 (also see Table S3 
and for corresponding references see Table S2). These targets mostly comprise genes from the top 2,000 list 
of differentially expressed genes. However, we also included targets not present in this list that either have a 
well-documented role in Stx trafficking, thus serving as controls, or are interaction partners of one of the other 
Figure 3. Differential gene expression of Stx2a-sensitive ACHN and Stx2a-refractory Caki-2 cells upon 
Stx2a exposure in comparison to untreated cells. (a) PCA of RNAseq data for ACHN and Caki-2 cells under 
different conditions, i.e. exposure to Stx2a for 4 h or 8 h and untreated control. The respective conditions with 
three biological replicates each are portrayed with distinct colours. (b,c) MA plots of genes in ACHN cells (b) 
or Caki-2 cells (c) two times or more up- or down-regulated after 4 h or 8 h of Stx2a challenge, respectively. 
Statistically significant genes out of ≈21,000 with nonzero total read count (p < 0.01) with an at least twofold 
change are plotted in red. Triangles indicate genes outside the fold change scale.
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analysed targets. Additionally, because Stx trafficking was shown to be independent of coat protein/coatomer I 
(COPI) vesicles33,34, we included the COPI subunit COPB2 to serve as a negative control.
The success of the siRNA silencing experiments in ACHN cells was shown by RT-PCR, whereby the knock-
downs resulted in a significant decrease in mRNA down to 5% to 65% in range in comparison to the negative 
control siRNA (NC), with a median of 23% (Fig. S4a). To disclose a possible harmful effect of the siRNA treat-
ment itself, the extent of cytotoxicity due to individual siRNAs as well as mixtures of siRNAs for various targets 
was determined (Fig. S4b). Though transfection per se (see mock- and NC-transfected samples versus untrans-
fected samples) had a modest effect on ACHN cell viability, a statistically significant detrimental effect was only 
observed for six siRNAs, namely TSG101, NEDD4, RAB9A, BICD1, COPB2, and GOLGA1. However, none of 
these knockdowns had such a strong effect on viability as the PLK1 cell death control. Moreover, when compared 
to PLK1, three of the aforementioned targets (RAB9A, BICD1, and GOLGA1) showed statistically significant 
higher viability (statistical comparison to PLK1 is not included in Fig. S4b). Thus, as these knockdown experi-
ments were successful, and the siRNA transfection had mostly insignificant effects on cell viability, we proceeded 
to use the knockdown approach for Stx2a inhibition experiments.
Silencing of RAB5A, TRAPPC6B, and YKT6 abrogates Stx2a intoxication of ACHN cells. After 
ACHN cells were treated with siRNA, they were exposed to Stx2a for 72 h followed by viability measurements 
(Fig. 7). The cell viability of Stx2a-exposed but otherwise only NC- or untransfected cells (controls) ranged from 
15 to 25%. Many of the individual or mixed knockdowns exhibited a low but significant increase or decrease in 
viability compared to the controls (see Table S5). However, to focus on biologically relevant refractory effects, 
we only considered targets the knockdown of which resulted in at least doubled cell viability (30%) compared to 
NC- and Stx2a-exposed controls (15%).
In the endosomal group of targets (Fig. 7a), knockdown of RAB5A as well as that of a mixture of RAB5A with 
its guanine nucleotide exchange factor (GEF), RABGEF1, and two of its effectors, VPS11 and VTI1A (RRVVmix), 
elicited a relevant increase in cell survival up to 62.7% and 55.3%, respectively. As targeting RAB5A alone had a 
slightly higher refractory effect than using the RRVVmix, no other components in the RRVVmix seem to influ-
ence Stx2a sensitivity.
In the RAB6A-centered Golgi group of targets (I, Fig. 7b), none of the tested individual or combined knock-
downs (except RTYmix, see below) caused a relevant refractory effect except for a slight beneficial effect indicated 
by 31.7% cell survival when targeting DYNLL1. However, unlike the RAB5A mixtures, mixtures of DYNLL1 with 
other microtubule-associated factors, namely DCTN4 and BICD1 (DDBmix), did not produce an increase in cell 
survival. No effect was seen for knocking down COPB2, which was expected as this was a negative control (see 
above).
In the other group of Golgi targets (II, Fig. 7c), knockdown of TRAPPC6B, as well as YKT6, increased the 
viability relevantly up to 37.5% and 68.6%, respectively. However, similar to DYNLL1, mixtures of TRAPPC6B 
with other tethering factors, namely GOLGA1 and COG3 (GTCmix), and mixtures of YKT6 with other SNAREs, 
namely STX5, GOSR1, and BET1L in the S1LYmix (or BET1 in the S1TYmix, as in Fig. 7d), did not show a com-
parable increase in cell viability.
Regarding anterograde ER-Golgi trafficking-related SNAREs (a process unknown to participate in Stx traf-
ficking), neither GOSR2 or BET1 alone nor combinations of them with other SNAREs (S1TYmix and S2TSmix) 
Figure 4. Heatmaps of the top 20 genes with the highest variability in ACHN and Caki-2 cells when exposed to 
Stx2a. Heatmap colour corresponds to the amount by which a gene expression variance deviates from the gene’s 
mean variance across all nine samples in each cell line with three samples per condition, i.e. 4 h or 8 h Stx2a 
exposure and untreated control. Genes and conditions are clustered according to their sample similarities. The 8 
genes shared by both ACHN and Caki-2 cells in the top 20 list (out of ≈21,000 genes) are highlighted in green.
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showed a relevant refractory effect (Fig. 7d). Lastly, no beneficial effect was detected for the remainder of the 
individual or mixed retrograde Golgi-ER trafficking components (Fig. 7d).
Finally, using a mixture that knocked down all of the targets that had prominent benefits for cell survival, 
namely RAB5A, TRAPPC6B, and YKT6 (RTYmix), we found a cumulative refractory effect, whereby silencing 
increased viability up to 81.3% (Fig. 7b); hence, this mixture almost completely prevented Stx2a toxicity.
To test whether the duration of the Stx2a challenge influences the refractory effect of selected individual or 
combined siRNA knockdowns, we reduced the time of Stx2a exposure from 72 h to 48 h (Fig. 8), another common 
incubation time for Stx cytotoxicity assays35. The reduced exposure time of 48 h resulted in an overall elevated via-
bility in comparison to 72 h, which was then further increased from 52.2% of NC-transfected and Stx2a-exposed 
cells by targeting single components to 82.2% with RAB5A, 71.2% with TRAPPC6B, or 92.4% with YKT6 (though 
gene symbol biological role
cluster in 
Figure 5a
genes with higher expression in ACHN cells and a known role in Stx trafficking
ATP6V0A1, ATP6V0D1, 
and APT6V1G1 vacuolar ATPase components ─
BICD1 RAB6A- and dynein-interacting golgin/CCTb ─
BNIP1 ER-localised SNARE, in complex with STX18/USE1/SEC22B i
COG3/SEC34 component of the Golgi-localised COGc MTCd i
DYNLL1 one of the light chains of the microtubule motor dynein ─
GOLGA1/golgin-97 ARL1-interacting golgin/CCT i
GOSR1/GS28 Golgi-localised SNARE, in complex with STX5/BET1L/YKT6 i
STX5 Golgi-localised SNARE, in complex with GOSR1/BET1L/YKT6 i
TBC1D17 deactivating RAB8 and RAB21 GAPe i
VAMP2 plasma membrane-localised SNARE i
VPS11 core component of the endosomal CORVETf/HOPSg MTCs, RAB5 effector ─
genes with higher expression in Caki-2 cells and a known role in Stx trafficking
ARL1 Golgi-localised small GTPase ─
BICD2 RAB6A-interacting golgin/CCT ─
RAB11A small GTPase, master regulator of the recycling endosome ─
genes with higher expression in ACHN cells and an unknown role in Stx trafficking
DCTN4 component of the integral dynein-interacting dynactin complex ─
DENND5A/RAB6IP1 putative activating RAB6 GEFh ─
NEDD4 ubiquitin ligase, part of the ESCRTi pathway ii
NEDD4L ubiquitin ligase, part of the ESCRT pathway ii
RAB5A small GTPase, master regulator of the early endosome i
RAB9A late endosomal small GTPase i
RABGEF1/rabex-5 major activating RAB5 GEF i
TRAPPC6B core component of the Golgi-localised TRAPPj MTCs i
TSG101 ESCRT-I component ii
USE1 ER-localised SNARE, in complex with STX18/BNIP1/SEC22B i
other genes analysed with a known role in Stx trafficking
BET1L/GS15 Golgi-localised SNARE, in complex with STX5/GOSR1/YKT6 —
NBAS/NAG component of the ER-localised NRZk MTC —
RAB6A small GTPase, master regulator of intra-Golgi trafficking —
VTI1A endosomal/Golgi SNARE, RAB5 effector —
YKT6 Golgi-localised SNARE, in complex with STX5/GOSR1/BET1L —
other genes analysed with an unknown role in Stx trafficking
BET1 ER/Golgi-localised SNARE, in complex with STX5/GOSR2/SEC22B —
COPB2 component of the COPIl vesicle coat —
GOSR2/GS27 ER/Golgi-localised SNARE, in complex with STX5/BET1/SEC22B —
SEC22B ER/Golgi-localised SNARE, in complex with STX18/BNIP1/SEC22B or STX5/GOSR2/BET1 —
STX18 ER-localised SNARE, in complex with BNIP1/USE1/SEC22B —
Table 1. Selected target genes of ACHN and Caki-2 cells and their biological role. a'–', neither part of cluster i 
nor ii. bCCT, coiled-coil tether. cCOG, conserved oligomeric complex. dMTC, multisubunit tethering complex. 
eGAP, GTPase-activating protein. fCORVET, class C core vacuole/endosome tethering. gHOPS, homotypic 
fusion and protein sorting. hGEF, guanine nucleotide exchange factor. iESCRT, endosomal sorting complex 
required for transport. jTRAPP, transport protein particle. kNRZ, NAG-RINT1-ZW10. lCOPI, coat protein I/
coatomer.
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the beneficial effect of DYNLL1 was less pronounced, with 64.3%). Remarkably, knockdown with the RTYmix 
reached 99.5%, producing virtually a full inhibition of the Stx2a intoxication.
Taken together, by using RNAi in ACHN cells aimed at a panel of targets involved in intracellular trafficking 
and then exposing them to Stx2a, we were able to identify three major targets as being pivotal in determining the 
differing Stx susceptibilities of ACHN and Caki-2 cells, i.e. RAB5A, TRAPPC6B, and YKT6. Two of these, RAB5A 
and TRAPPC6B, constitute completely novel and unprecedented host factors in Stx biology. Silencing these two 
factors in combination with YKT6 reverted the devastating cytotoxic action of Stx.
Discussion
As the renal epithelium is an important Stx target during HUS11, new research is needed to elucidate in detail the 
interactions of Stx with these cells. Here, we investigated two renal epithelial cell lines, ACHN and Caki-2, which 
have strikingly opposing responses to Stx intoxication. By understanding this difference in more detail, our study 
offers an opportunity to protect the renal epithelium in vivo.
While previous studies have determined, using TLC or flow cytometry, that Stx was able to access the recep-
tor Gb3Cer on ACHN cells36,37, such studies had not been performed for Caki-2 cells. To address this, here we 
used immunofluorescence microscopy to show that Stx2a could access ACHN as well as Caki-2 cells (Fig. S2). 
Furthermore, using TLC overlay assays, we detected identical Gb3Cer binding profiles of Stx2a for both ACHN and 
Caki-2 cells (Fig. 2b). Additionally, by providing specific structural data, our work supplements previous findings 
that Gb3Cer is definitively present on ACHN cells, which was found by employing antibodies either by flow cytome-
try30,36 or by TLC37. Moreover, it clarifies the previous finding from a study using flow cytometry that Gb3Cer is only 
marginally present on Caki-2 cells30. Here, for the first time, we present high-resolution mass spectrometry data on 
various Gb3Cer lipoforms shared by both ACHN and Caki-2 cells, unequivocally showing that Gb3Cer is present 
on both cell types (Fig. 2c). In sum, while these findings are in perfect agreement with early studies on ACHN cells 
that described their high sensitivity to Stx29, which is also what we found here (Fig. 1), these data do not explain why 
Caki-2 cells are refractory to Stx, as shown before30 and in our study (Fig. 1). Indeed, the Stx2a binding to ACHN 
and Caki-2 cells differs to some extent (Fig. S2), which might result in the contrasting sensitivity and definitely needs 
further analysis in the future. However, the virtually equivalent Stx receptor profiles and the fact that single Stx mol-
ecules suffice to kill cells32 prompted us to instead apply a high-throughput approach for transcriptomic profiling 
using RNAseq to unravel why apparently similar renal epithelial cells have such opposite sensitivities to the toxin.
Transcriptomic profiling after Stx challenge has been previously executed by microarray analyses. These 
studies used human umbilical vein endothelial cells38, human macrophage-like THP-1 cells39, and human der-
mal neonatal microvascular endothelial cells40, and differential expression was found for 38, 36, and 369 genes, 
respectively. Here, our RNAseq data suggest that the cellular response to Stx exposure encompasses a wider set 
of affected genes (Fig. 3), which may have been difficult to observe in previous studies, as microarray techniques 
are less sensitive than RNAseq.
When comparing the top 20 genes we found to be most notably affected by Stx (Fig. 4) with the genes found 
in the previous microarray studies, it becomes obvious that in all the studies five out of the eight genes common 
between ACHN and Caki-2 cells are upregulated, namely ATF3, DUSP1, EGR1, TRAF1, and TNFAIP3. Likewise, 
CXCL8/IL8, which is in the top 20 genes in Caki-2 cells but is upregulated in ACHN cells as well, was found to be 
affected by Stx in the aforementioned microarray studies. As most of these genes are related to inflammation, this 
strongly suggests that upon Stx intoxication these genes function in a cell type-independent inflammation-related 
way. Nevertheless, as these similarities do not disclose why ACHN cells are more sensitive to Stx than Caki-2 cells, 
we focused on differences that arose in response to a toxin challenge using time series analysis; this helped narrow 
our approach down to differences in trafficking pathways (Figs. 5 and 6).
Most importantly, the key targets we identified with regard to Stx intracellular trafficking, RAB5A and 
TRAPPC6B, are completely unprecedented. This underlines the power of our approach using RNAseq in the 
first place as it successfully recognised novel crucial factors in Stx biology which were missed in Stx trafficking 
research until now. Though the early steps of Stx trafficking, where the EE is the intracellular starting point, have 
been investigated in great detail21,22,24, no study has previously demonstrated the direct involvement of RAB5A, 
the master regulator of trafficking at the EE; in fact, one study even showed that Stx transport to the Golgi appa-
ratus was independent of RAB5A41. In contrast, here, for the first time, we revealed that RAB5A crucially par-
ticipates in Stx trafficking in ACHN cells (Figs. 7a and 8), which is reasonable regarding its biological function. 
This discrepancy from previous work can be explained by the use of different cell lines: we used renal epithelial 
ACHN cells, whereas previous work used renal fibroblast COS-7 and cervical epithelial HeLa cells. Additionally, 
other methodology might contribute to this discrepancy as well, i.e. we used Stx cytotoxicity analyses, whereas 
previous work used Stx uptake assays and microscopy for readout, which does not directly assess cell viability. 
Together, these factors could have caused previous work to overlook RAB5A’s essential role in Stx toxicity. This 
is corroborated by a recent genome-wide CRISPR/Cas screen performed in urinary bladder epithelial 5637 cells 
that used cytotoxicity as readout; it provided RAB5A as a hit42.
Three recent genome-wide screens for Stx cytotoxicity have been conducted, one using RNAi43 and two using 
CRISPR/Cas42,44. In comparison to these studies, our approach, besides applying RNAseq for the first time to 
explore Stx-host interaction, has substantial advantages. First, in contrast to disease-unrelated cell types, we used 
actual pathogenesis-involved cell types. Second, our approach of using RNAseq first, in contrast to using RNAi 
directly from the beginning or using CRISPR/Cas, most likely helped us identify host factors that otherwise 
would appear as false negatives or only as minor hits, e.g. due to their essentiality; in fact, this might be why 
RAB5A was not identified earlier. Thus, our approach to combine RNAseq with RNAi merges the advantages of 
both techniques. Moreover, RNAseq, suitable for short incubation intervals, can be especially helpful in uncov-
ering the factors at play in the early responses to Stx, which are potentially masked by RNAi or CRISPR/Cas, 
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as these approaches are usually applied on the scale of days. Our approach also has certain limitations: in case 
of highly stressed conditions upon Stx2a exposure, significantly upregulated genes are not only the ‘targets’ for 
Stx but also the ‘consequences’ of Stx cytotoxic action. However, examining the functional relationship between 
upregulated genes allows for selecting potential candidates for RNAi experiments, which are not surprisingly 
trafficking genes. In this case, RNAseq is an approach that can point to particular genes in the trafficking pathway, 
worth selecting as cell type-specific candidates for RNAi. In the future, this approach should be tested using pri-
mary cells of kidney and brain with reduced Stx incubation time.
Altogether, our study revealed, and future studies using our approach will help to reveal, crucial factors in Stx 
biology that can potentially be exploited for novel therapeutic applications. This is of outstanding importance, as 
non-bacterial targets (those that do not require antibiotics) are desperately needed to treat the life-threatening condi-
tions caused by Stx.
Figure 5. Interaction network of selected genes with higher expression in ACHN versus Caki-2 cells upon Stx2a 
exposure. A total of 143 genes with enhanced expression, listed in Table S3, was selected from the top 2,000 list of 
differently expressed genes of ACHN versus Caki-2 cells. STRING database (confidence view) was used for the 
visualisation of the interaction of genes located at the endosomal system, the Golgi network, or the ER including 
TGN, cis-Golgi network, and ER-Golgi intermediate compartment according to Gene Ontology (with VPS11 from 
Table S3 missing in the figure due to its absence from STRING). Borders delineate the two clusters i and ii being 
interconnected by an edge confidence of ≥0.7, from which genes were subsequently analysed.
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Methods
Cell culture and cytotoxicity assays. Human kidney epithelial cell lines were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA). ACHN (ATCC, CRL-1611) and Caki-2 (ATCC, 
HTB-47) epithelial cell lines were adapted to and cultivated at 37 °C in a humidified 5% CO2 atmosphere in 
OptiPROTM serum-free medium (#12309–019, Gibco Life Technologies Corporation, Paisley, UK), which 
excluded uptake and detection of exogenous GSLs from serum. Cell medium was additionally supplemented 
with 4 mM L-glutamine. ACHN and Caki-2 cells were cultured as needed in 25–175 cm2 tissue culture flasks 
(Greiner Bio-One, Frickenhausen, Germany) and passaged every 2–3 days using 0.25% Trypsin-EDTA (#25200, 
Invitrogen, Karlsruhe, Germany).
Stx2a was affinity-purified from the Stx2a-containing supernatant of E. coli strain 03–0616 (O111:H−) as 
previously described45 and proteins in the SDS-PAGE were stained with the Quick Coomassie Stain (35081.01, 
Serva, Heidelberg, Germany) using the Precision Plus Protein Dual Xtra Prestained Protein Standard as refer-
ence (5 µL, 1610377, Bio-Rad, Munich, Germany) (Fig. S1). Stx2a preparations were free of bacterial endotoxins 
as measured by the Pierce LAL Chromogenic Endotoxin Quantification Kit (#88282, Thermo Fisher Scientific, 
Dreieich, Germany).
The cytotoxicity of Stx2a was assessed with the crystal violet assay as previously described using the indicated 
concentrations (Fig. 1) or 40 pg/mL (Figs. 7 and 8). For RNAseq, ACHN and Caki-2 cells were exposed to Stx2a 
for 4 h and 8 h at a concentration of 0.4 µg/mL or were left unexposed (control condition). Three biological repli-
cates were prepared per cell line and condition.
Lipid reference, antibodies, and fluorophores. Neutral GSLs from human erythrocytes containing the 
Stx receptor GSLs Gb3Cer and Gb4Cer served as a positive control for orcinol staining and Stx2a TLC overlay 
assays (Fig. 2a,b)46.
Monoclonal mouse IgG anti-Stx2 antibody (clone VT 135/6-B9, 2.75 mg/mL, SIFIN GmbH, Berlin, Germany) 
was used for TLC overlay assays (Fig. 2b) and for immunofluorescence imaging (Fig. S2). Highly cross-absorbed 
Figure 6. Intracellular trafficking of Stx and cellular targets silenced by RNAi. Depicted is the common 
trafficking route of Stx upon attachment to its receptor Gb3Cer in the vicinity of sphingomyelin (bright blue 
circle with grey tail) and cholesterol (orange structure with small blue head). After internalisation, retrograde 
transport to the EE and then through the Golgi apparatus to the ER, and processing of the Stx A subunit, the 
A1 fragment is retrotranslocated to the cytosol and exerts its cytotoxic function on ribosomes. Indicated are 
host genes of ACHN cells targeted with siRNAs prior to Stx2a exposure. Highlighted in red are those genes that 
exhibited higher expression in ACHN compared to Caki-2 cells with regard to RNAseq data. Asterisks denote 
those targets, where an siRNA-mediated knockdown resulted in most substantial refractiveness to Stx2a-caused 
cell injury of ACHN cells (see also Fig. 7).
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Alexa Fluor 488 goat anti-mouse IgG antibody (#A11029, Thermo Fisher Scientific) was used for immunofluo-
rescence imaging (Fig. S2). Secondary alkaline phosphatase (AP)-conjugated affinity-purified polyclonal goat 
anti-mouse IgG antibody (code 115–055–003, Dianova, Hamburg, Germany) was used for TLC overlay assays 
(Fig. 2b). WGA conjugated to Alexa Fluor 647 (#W32466, Thermo Fisher Scientific), goat anti-mouse IgG anti-
body conjugated to Alexa Fluor 488 (#A11029, Thermo Fisher Scientific), and 4′,6-diamidino-2-phenylindole 
(DAPI, #D9542, Sigma-Aldrich, Taufkirchen, Germany) were used for immunofluorescence imaging (Fig. S2).
GSL isolation and TLC overlay assays. GSLs were extracted from confluently grown total cells with 
methanol and various chloroform/methanol mixtures. Coextracted glycerophospholipids and triglycerides 
were removed by mild saponification. Neutral GSLs were separated from acidic GSLs by anion-exchange col-
umn chromatography using DEAE-Sepharose CL-6B (GE Healthcare, Munich, Germany) according to stand-
ard procedures46 and finally dissolved in chloroform/methanol (2/1, v/v). Purified neutral GSLs were applied to 
Figure 7. Survival of ACHN cells upon application of siRNA prior to 72 h Stx2a exposure. ACHN cells were 
not transfected or were reverse transfected with a scrambled NC or the indicated siRNA(s) directed towards 
the following targets: endosomal targets (a), two different sets of Golgi-targets (b,c), and Golgi-ER trafficking 
targets (d). Then, cells were incubated without or with Stx2a for 72 h. Cell viability upon application of siRNA 
and Stx2a is depicted as the percentage related to untreated cells alongside with boxplots. Each biological 
replicate (n = 3) shown in different colours (orange, magenta, and blue) was technically replicated a further 
seven times. Median values from 21 measurements each of transfected and non-transfected controls are shown 
as dotted and dashed lines, respectively. Approaches without Stx2a are displayed in green and those with Stx2a 
in red. Measured values of non-transfected cells without Stx2a were set as 100% viability. Spaces indicate that 
data was taken from different sets of microtiter plates. For separate plots depicting all controls refer to Fig. S5a. 
Statistical analysis is based on linear models. Asterisks above boxplots indicate levels of significance in relation 
to NC- and Stx2a-exposed cells (red, dotted line) and are only given for knockdowns with at least 15% difference 
to control and 30% viability (i.e. two-fold difference): ***p < 0.001. Abbreviations: mix, mixture; RRVVmix, 
RABGEF1, RAB5A, VPS11, and VTI1A; DRmix, DENND5A and RAB6A; DDBmix, DYNLL1, DCTN4, and 
BICD1; RTYmix, RAB5A, TRAPPC6B, and YKT6; GTCmix, GOLGA1, TRAPPC6B, and COG3; S1LYmix, 
STX5, GOSR1, BET1L, and YKT6; S1TYmix, STX5, GOSR1, BET1, and YKT6; S2TSmix, STX5, GOSR2, BET1, 
and SEC22B; SBUSmix, STX18, BNIP1, USE1, and SEC22B.
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high-performance TLC plates precoated with silica gel 60 (size: 10 cm × 10 cm; thickness: 0.2 mm; #1.05633.0001, 
Merck, Darmstadt, Germany) with an automated sample applicator (Linomat 5, CAMAG, Muttenz, Switzerland). 
Subsequently, neutral GSLs were separated in chloroform/methanol/water (120/70/17, v/v/v) and stained with 
orcinol or subjected to TLC overlay assays as previously described46,47. Shortly, Gb3Cer was detected with Stx2a 
combined with a primary anti-Stx2 and an AP-conjugated secondary antibody.
Mass spectrometry of Gb3Cer. MS1 and MS2 analysis of Gb3Cer was performed using a SYNAPT G2-S 
mass spectrometer (Waters, Manchester, UK) equipped with a Z-spray source as previously described45,47. 
Purified neutral GSLs from ACHN and Caki-2 cells were analysed in the positive ion sensitivity mode. Structures 
of individual GSLs were detected as singly charged monosodiated [M + Na]+ ions and structures were deduced 
from CID spectra.
Immunofluorescence microscopy. ACHN and Caki-2 cells were seeded at a concentration of 1 × 105 
cells/mL (final volume 0.2 mL)  in 8-well polystyrene chamber slides (#177445, Thermo Fisher Scientific) and 
cultured for two days until ~80–90% of confluence. To facilitate the assessment of the subcellular distribution of 
the toxin receptors and for the purposes of the fluorescent signal normalisation, the surface of the plasma mem-
brane of the cells was pre-stained with WGA-Alexa Fluor 647 for 15 min prior to fixation, quenching, and incu-
bation with the toxin. Afterwards, cells were fixed with 3.7% paraformaldehyde (Merck) for 30 min, quenched 
with 0.2 M glycine, pH 7.2 (Carl Roth, Karlsruhe, Germany) for 15 min, and incubated with Stx2a (0.5 μg/mL) for 
1 h. Stx2a-exposed samples were then incubated with anti-Stx2a antibody in 1:500 dilution with 1% BSA at 4 °C 
overnight followed by Alexa Fluor 488-coupled antibody for 1 h. Nuclear DNA was stained with DAPI for 10 min. 
Finally, slides were mounted with Immunoselect Antifading Mounting Medium (#SCR-038447, Dianova).
The Stx2a immunostained preparations (3 biological replicates) were accompanied by mock-immunostained 
samples (2 biological replicates) which were treated identically to the experimental samples with the omission of 
Stx2a. Immunofluorescence imaging was performed with Leica SP8 confocal laser scanning microscope equipped 
with an HC PL Apo CS2 63x NA 1.4 oil immersion objective and HyD detectors for photon counting (Leica, 
Wetzlar, Germany). Collected confocal stacks are presented as maximum intensity XY projections and trans-
verse XZ and YZ sections. To quantify the difference in Stx2a binding between ACHN and Caki-2 cells we first 
established the background fluorescence level which was obtained by staining both cell lines with WGA and both 
primary and secondary antibodies without adding the toxin. For this, the cumulative unspecific antibody signal 
from each stack obtained from the mock-immunostained samples (n = 31 and n = 51 for ACHN and Caki-2 
cells, respectively) was normalised against the cumulative WGA signal of each respective stack (antibody/WGA 
ratio). Here, the WGA signal provides a way to approximate the total cell surface available for toxin binding. Such 
a normalisation ensures that the result is independent of the cell geometry, the number of cells within the field of 
view, and the stack dimensions. The fact that the baseline antibody/WGA ratio is nearly consistent between the 
two cell lines (0.32 versus 0.35 for ACHN and Caki-2 cells, respectively) confirms the utility of such an approach. 
Figure 8. Survival of ACHN cells upon application of siRNA for selected most promising targets prior 
to 48 h Stx2a exposure. Experimental details correspond to those of Fig. 7 except that Stx2a exposure was 
shortened to 48 h. Depicted are three biological replicates (n = 3) each performed in septuplicate. Median 
values from 21 measurements each of transfected and non-transfected controls are shown as dotted and dashed 
lines, respectively. Approaches without Stx2a are displayed in green and those with Stx2a in red. Results of 
non-transfected cells without Stx2a were set as 100% viability. For separate plots depicting all controls, see 
Fig. S5b. Statistical analysis was performed against NC- and Stx2a-treated cells with linear models: **p < 0.01; 
***p < 0.001.
13Scientific RepoRtS |         (2020) 10:4945  | https://doi.org/10.1038/s41598-020-59694-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Once the baseline antibody/WGA ratio has been established, the fluorescence signal in the presence of the toxin 
was scored as the difference between this signal and the background for each respective cell line (n = 115 and 
n = 92 for ACHN and Caki-2 cells, respectively). The imaging data were processed and analysed with ImageJ 
1.51 h (National Institutes of Health, USA).
RNA isolation and RNA sequencing. Total RNA was purified from ACHN and Caki-2 cells using the 
TRIzol Reagent (Thermo Fisher Scientific) following the manufacturer’s instructions. We performed a qual-
ity check and quantification of total RNA with the Bioanalyzer RNA 6000 Nano Kit (Agilent Technologies). 
mRNA-Seq libraries were prepared from 1 μg of total RNA (RIN > 9.6) using the Agilent SureSelect 
Strand-Specific RNA Library Prep following the manufacturer’s instructions. 36 bp single-end sequencing was 
conducted using a HiSeq 3000 machine (Illumina) and the sequence summary is presented in Table S1.
Bioinformatic analysis of RNAseq data and visualisation. The quality of the RNAseq reads was 
assessed with FastQC software (v0.11.5, http://www.bioinformatics.babraham.ac.uk/projects/fastqc). RNAseq 
reads were mapped to human reference genome version GRCh38.87 with the TopHat2 aligner (v2.0.13)48. 
Mapped reads (in bam format) were processed with SAMtools (v1.3.1, http://samtools.sourceforge.net): bam 
files were sorted by query name and multiple alignments were removed. Unique alignments in bam format were 
subsequently used in gene-level exploratory analysis and differential expression using R (v.3.4.1)49 and DESeq2 
package (v1.16.1) following instructions of Love and co-authors50. Briefly, gene models were defined using the 
pre-built transcript database TxDb.Hsapiens.UCSC.hg38.knownGene and count matrices were generated with 
the summarizeOverlaps function. Finally, a DESeqDataSet object was constructed and genes with counts < 1 were 
filtered out. The regularised-logarithm transformation (rlog) was applied prior to PCA to stabilize the variance 
across the mean. PCA was performed to visualize the variation between the groups (cells with Stx2a treatment 
and without) and within the groups (biological replicates). MA plots (minus/average; mean-difference plots) 
were constructed to visualize the changes induced by Stx2a treatment. Time-series analysis was performed to find 
genes most differentially expressed in ACHN and Caki-2 cells in response to Stx2a treatment, taking into account 
different gene expression in these cells under control conditions (no Stx2a). Figures outside the DESeq2 package 
were created using R package ggplot251 and Adobe Photoshop CC 2017.
RNA interference via reverse transfection. For RNAi individual siRNAs were ordered from Qiagen 
(Hilden, Germany) with the scrambled AllStars siRNA serving as NC. For a full list see Table S4. First, the amount 
for an end concentration of 5 nM per siRNA was spotted onto 96-well plates (Greiner Bio-One). A mixture of 
all siRNAs targeting a gene was applied where available. Next, a mixture of the transfection reagent HiPerFect 
(Qiagen) and ACHN cell culture medium was applied and incubated for 10 min at RT. Then, 9,000 cells per well 
in medium were added and incubated for 48 h at 37 °C in a humidified atmosphere containing 5% CO2. If subse-
quent Stx2a exposure was performed, the toxin was applied for another 48 h or 72 h. Cytotoxicity measurement 
with knockdowns alone or with additional Stx2a treatment was executed as described above.
RNA isolation for RT-PCR. After reverse transfection with different siRNAs, total RNA of cells was 
extracted using the RNeasy Mini Kit following the manufacturer’s instructions (Qiagen). Homogenisation dur-
ing extraction was performed using Qiagen QIAshredder columns. Next, RNA was digested with the Turbo 
DNA-free Kit (Thermo Fisher Scientific) following the manufacturer’s instructions. Then, 2 ng of DNase-digested 
RNA was used for one-step RT-PCR with the QuantiTect SYBR Green RT-PCR Kit (Qiagen). The housekeeping 
gene GAPDH was selected as reference52. The primers used for the control of individual target knockdowns were 
selected employing the PrimerBank database53,54. Primers for those as well as GAPDH are listed in Table S4. The 
primer concentration was 500 nM each and for each primer pair the primer efficiency was determined. RT-PCR 
was performed in triplicates in 96-well plates in a CFX96 machine (Bio-Rad). Relative expression was determined 
using the 2−ΔCt method55,56 with GAPDH expression set as 100%. Results were plotted using ggplot2.
Statistical analysis. Statistical analysis was performed in R (v.3.4.1)49. Cytotoxicity assays with Stx2a (Fig. 1) 
or siRNA only (Fig. S4b) as well as Stx2a assays with siRNA pre-treatment (Figs. 7 and 8) were analysed using 
mixed effects models in R with the nlme package57. Briefly, in case of mixed effects models for cytotoxicity assays 
(Fig. 1), treatment with Stx2a (‘treatment’) was set as a fixed effect and biological replicates were set as random 
factors (random = ~1|replicate). The model also took into account differences in variances between treatment 
groups (weights = varIdent (form = ~1|treatment)):
∼ = ∼ |
= ∼ | = ″ ″
nlme (viability treatment, random 1 replicate,
weights varIdent (form 1 treatment), method REML ) (1)
The same approach was applied for cytotoxicity assays with siRNAs only (Fig. S4b) and Stx2a assays with 
siRNA pre-treatment (Figs. 7 and 8) with the difference that siRNAs were set as fixed effects instead of Stx2a treat-
ment. Validations of the statistical models for Figs. 1, S4b, 7 and 8 are provided in Fig. S6a–d, respectively. For the 
summaries of the statistical models used for data from Figs. 1, S4b, 7 and 8 see Table S5.
ANOVA was performed in order to estimate if there are differences between siRNA knockdowns in ACHN 
cells. Multiple comparisons of siRNA knockdowns were performed using t-tests (n = 3) and p-values were 
adjusted for multiple comparisons using the Holm method (Fig. S4b).
Time-series analysis to reveal cell-specific responses to Stx2a exposure was performed in the DESeq2 package 
as described by Love et al.58. Briefly, we modelled the cell difference (ACHN/Caki-2) at time point 0 (control), the 
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difference over 4 h and 8 h of Stx2a exposure (treatment), and any cell-specific difference over time points (the 
interaction term ‘cell:treatment’):
< − ∼ + +ddsTC DESeqDataSet ( cell treatment cell: treatment) (2)
Next, we performed a likelihood ratio test (LRT) where cell-specific differences were removed:
< − = ′ ′ = ∼ +ddsTC DESeq (ddsTC, test LRT , reduced cell treatment) (3)
The output of this test was a list of genes with small p-values that showed cell-specific effect after time point 0. 
Genes that moved up or down similarly over time were not given priority by this model design.
Accession code. The RNAseq data are  available at the European Nucleotide Archive (Accession number 
PRJEB33446). Other relevant data are presented in supplementary materials or will be provided by the corre-
sponding authors upon request.
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